Key takeaways
- Thymosin beta-4 (Tβ4) is a 43-amino-acid protein present in almost every cell, where its primary job is to hold actin monomers in reserve so the cytoskeleton can be rebuilt quickly.
- TB-500 is a synthetic peptide containing the seven-residue actin-binding segment of Tβ4; nearly all of the published biology concerns the full-length protein, not the fragment.
- In animal models, full-length Tβ4 accelerated skin wound closure, promoted endothelial and cardiac cell migration, and mobilized epicardial progenitor cells after heart injury.
- Pharmaceutical-grade Tβ4 has completed Phase 1 safety studies and Phase 2 trials in dry eye; none of these involved TB-500, and no Tβ4 product is approved.
Most peptides in the tissue-repair literature were designed or discovered as drugs. Thymosin beta-4 was not. It is one of the most abundant small proteins in the human body, found in nearly every cell type at concentrations high enough to be visible in a routine protein gel, and its day job, regulating the pool of free actin, was worked out by cell biologists with no therapeutic agenda. The repair story came later, when researchers noticed that a protein controlling how cells move might influence how tissues close after injury. TB-500, the name under which a fragment of Tβ4 circulates in research catalogs, sits at the edge of that literature. This note explains the protein, the evidence, and exactly where the fragment fits.
What thymosin beta-4 is
Tβ4 was first isolated from calf thymus in the 1960s as one of a family of “thymosins” thought to be thymic hormones. That framing turned out to be wrong: Tβ4 is made by nearly all cells, not just the thymus, and it is not a hormone in any conventional sense. It is a 43-amino-acid, highly acidic, largely unstructured protein of about 4.9 kDa with an acetylated serine at its N-terminus. In 1991, Safer, Elzinga and Nachmias showed that Tβ4 was identical to a factor they had purified from platelets as the principal actin-sequestering component of the cytoplasm.1 That finding relocated the protein from immunology to cell biology, where it has stayed.
Actin exists in cells as single subunits (G-actin) and as filaments (F-actin). The balance between them determines how a cell moves, changes shape and divides. Tβ4 binds G-actin one-to-one and prevents it from joining filaments, which sounds inhibitory but is actually a storage function: cells keep a large reserve of monomer bound to Tβ4 so that when a signal arrives, actin can be released and polymerized on demand. Intracellular Tβ4 concentrations reach hundreds of micromolar in some cell types, matching the size of the actin pool it manages.2 The actin-binding region was mapped to a short central segment, residues 17 to 23, with the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ), although structural work has since shown that most of the protein’s length contacts actin when bound.
From cytoskeleton to repair
The transition from cell biology to repair biology came in the late 1990s from Hynda Kleinman’s laboratory at the US National Institutes of Health. Malinda and colleagues made full-thickness skin wounds in rats and applied Tβ4 either topically or by intraperitoneal injection. Treated wounds closed faster, showed more collagen deposition and contained more new blood vessels than controls. In parallel, Tβ4 increased keratinocyte migration in culture, consistent with its role in the actin machinery cells use to crawl.3 Later work from the same group asked whether the actin-binding segment alone was responsible. Philp and colleagues synthesized peptides spanning parts of Tβ4 and found that the seven-residue actin-binding motif, and not other regions, reproduced the pro-angiogenic activity of the full protein in endothelial migration and vessel-growth assays.4 That 2003 paper is the most direct published support for the idea that a short fragment of Tβ4 retains part of its biology, and it is the scientific ancestor of TB-500.
Goldstein, Hannappel and Kleinman summarized the field in 2005 under a title that captures the shift: an actin-sequestering protein that “moonlights” to repair injured tissue.2 Their review proposed that the same property, mobilizing actin for cell movement, explains why Tβ4 promotes migration of keratinocytes, endothelial cells and, as the cardiac work would show, heart cells. They also noted anti-inflammatory effects and the involvement of a Tβ4 breakdown product, the tetrapeptide Ac-SDKP, in some observations.
Thymosin beta-4 was never a drug candidate looking for a mechanism; it was a mechanism that happened to look like a drug.
The cardiac models
The highest-profile Tβ4 papers are two studies in Nature. In 2004, Bock-Marquette and colleagues screened for factors that promoted cardiac cell migration and identified Tβ4. In mice given experimentally induced heart attacks, systemic or intracardiac Tβ4 reduced the area of dead tissue, improved cardiac function measured by echocardiography and increased survival of cardiomyocytes. Mechanistically, Tβ4 formed a complex with the enzyme PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt.5 In 2007, Smart and colleagues showed a different route to the same end: Tβ4 stimulated the epicardium, the heart’s outer cell layer, to release progenitor cells that migrated into the muscle and formed new blood vessels, a process the adult heart normally does not perform.6 Both findings were in mice, and later attempts to translate them into larger animals and humans have been slower and less clear-cut than the original papers suggested.
Human trials of pharmaceutical Tβ4
A single company, RegeneRx Biopharmaceuticals, has carried Tβ4 into clinical development under three formulations: RGN-259, an eye drop; RGN-137, a topical gel for skin wounds; and RGN-352, an injectable for cardiac and neurological indications. Crockford and colleagues, from RegeneRx, reviewed the program’s rationale and status in 2010.7 The same year, Ruff and colleagues published the Phase 1 study of intravenous Tβ4 in healthy volunteers, single and multiple ascending doses, placebo-controlled, and reported that the protein was well tolerated with no dose-limiting adverse events at the doses studied.8
The furthest-advanced indication has been dry eye. Sosne and Ousler reported a Phase 2 trial in which 72 patients with dry eye were randomized to Tβ4 eye drops or placebo and challenged in a controlled adverse environment chamber; the Tβ4 group showed statistically significant improvement on some sign and symptom endpoints, though not on all.9 Subsequent Phase 3 studies in dry eye and neurotrophic keratopathy have produced mixed results and, as of this writing, no Tβ4 product has received marketing approval in any country.
| Feature | Thymosin beta-4 (Tβ4) | TB-500 |
|---|---|---|
| Length and mass | 43 amino acids; ~4,963 Da | Short synthetic peptide built around residues 17–23 (Ac-LKKTETQ); ~890 Da |
| Origin | Naturally occurring in nearly all human cells | Chemical synthesis only; not a natural product |
| Actin binding | 1:1 sequestration of G-actin1 | Contains the mapped actin-binding motif; sequestration capacity not equivalent |
| Preclinical literature | Extensive: skin, cornea, heart, CNS models2–6 | Minimal; one fragment-activity study4 |
| Human studies | Phase 1 IV safety; Phase 2–3 ophthalmic (RegeneRx)7–9 | None |
| Detection literature | Endogenous; doping tests target synthetic fragments | Equine and human anti-doping methods10 |
Where TB-500 fits
TB-500 is not a code name for thymosin beta-4. It is a synthetic peptide that reproduces the actin-binding segment of Tβ4, the LKKTETQ motif, typically with an N-terminal acetyl group, and it appears in the peer-reviewed literature mainly through anti-doping science. Ho and colleagues at the Hong Kong Jockey Club racing laboratory described it in 2012 as “a synthetic version of an active region of thymosin β4” and developed a liquid chromatography–mass spectrometry method to detect it in equine urine and plasma, prompted by its appearance in racing.10 Human anti-doping laboratories have since added it to their screening panels.
The scientific case for the fragment rests almost entirely on the 2003 finding that the actin-binding motif alone was sufficient for angiogenic activity in vitro.4 That is a real result from a credible laboratory, but it is one study, in cell and vessel-growth assays, and it does not establish that a seven-residue peptide reproduces the wound-closure, cardiac or anti-inflammatory effects of the 43-residue protein in animals. None of the animal repair studies, and none of the human trials, used TB-500. When a catalog or article cites Tβ4 research to describe TB-500, it is borrowing evidence from a different molecule. The two share a motif; they do not share a data set.
Reading the evidence
Tβ4’s repair biology is better supported than most peptides in this category: multiple independent laboratories, several species, clear mechanisms and a formal clinical program. The weakness is at the level of the fragment. Researchers working with TB-500 should treat it as a probe of the actin-binding motif, and should not assume that findings for full-length Tβ4, including the human safety data, transfer to it. Research-grade material of either kind is not the pharmaceutical product tested by RegeneRx.
Practical considerations for research
Full-length Tβ4 is a small protein that must be produced recombinantly or by long synthesis, is relatively unstable, and is expensive. The fragment is a short peptide that can be made cheaply and is stable when lyophilized, which is why it dominates research catalogs. That trade-off is legitimate as long as the label and the literature match. On a certificate of analysis, TB-500 should show a mass-spectrometry match near 890 Da for the acetylated heptapeptide, or the corresponding mass if a longer variant is specified, and an HPLC purity figure with the method stated. Wednesday lists TB-500 within its blended tissue-repair products alongside BPC-157; a companion note, BPC-157 vs. TB-500, compares the two compounds’ mechanisms, and per-lot results are in the COA library.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a naturally occurring 43-amino-acid protein. TB-500 is a short synthetic peptide containing the seven-residue actin-binding segment of that protein. Almost all published research, including all human trials, used full-length thymosin beta-4, not TB-500.
What does thymosin beta-4 do in the body?
Its main role is to bind free actin subunits and hold them in reserve so cells can rapidly rebuild their cytoskeleton when they need to move or change shape. Because cell migration is central to wound closure and blood-vessel growth, this housekeeping role connects to tissue repair in animal models.
Has thymosin beta-4 been tested in humans?
Yes. RegeneRx has run a Phase 1 intravenous safety study in healthy volunteers and Phase 2 and 3 trials of thymosin beta-4 eye drops for dry eye and neurotrophic keratopathy. Results have been mixed and no product has been approved. TB-500 itself has not been tested in humans.
Why is TB-500 banned in sport?
Anti-doping authorities prohibit substances with no approved use that could plausibly affect performance or recovery. TB-500 was detected in horse racing around 2010, and detection methods were published for equine and later human samples. It falls under WADA’s non-approved substances category.
What is the LKKTETQ sequence?
It is the segment of thymosin beta-4 spanning residues 17 to 23 that was mapped as the primary actin-binding site. A 2003 study found this motif alone reproduced the protein’s pro-angiogenic activity in cell assays. TB-500 is built around this sequence.
References & further reading
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029–4032. PMID 1999398
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. doi:10.1016/j.molmed.2005.07.004
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368. doi:10.1046/j.1523-1747.1999.00708.x
- Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103–2105. doi:10.1096/fj.03-0121fje
- Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472. doi:10.1038/nature03000
- Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. doi:10.1038/nature05383
- Crockford D, Turjman N, Allan C, Angel J. Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–189. doi:10.1111/j.1749-6632.2010.05492.x / PMID 20536467
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223–229. doi:10.1111/j.1749-6632.2010.05474.x
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877–884. doi:10.2147/OPTH.S80954
- Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. J Chromatogr A. 2012;1265:57–69. doi:10.1016/j.chroma.2012.09.043